BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 46.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu M, Chen H, Zhou S, Zheng L, Li X, Chu R, Chen W, Wang B, Wang M, Chai Z, Feng W. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. Nanotoxicology 2021;15:761-78. [PMID: 33961538 DOI: 10.1080/17435390.2021.1919329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 An Z, Liu Q, Zeng W, Wang Y, Zhang Q, Pei H, Xin X, Yang S, Lu F, Zhao Y, Hu Y, Feng Q. Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD. Hepatol Commun 2022. [PMID: 35384367 DOI: 10.1002/hep4.1948] [Reference Citation Analysis]
3 Chen Z, Liu J, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res 2021;128:1747-65. [PMID: 34043417 DOI: 10.1161/CIRCRESAHA.121.319059] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ni XX, Lian M, Wu HM, Li XY, Sheng L, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Hua J. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. World J Gastroenterol 2021; 27(1): 80-91 [PMID: 33505152 DOI: 10.3748/wjg.v27.i1.80] [Reference Citation Analysis]
5 Xu X, Nan Y. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease". J Hepatol 2021:S0168-8278(21)02170-X. [PMID: 34774637 DOI: 10.1016/j.jhep.2021.11.003] [Reference Citation Analysis]
6 Chen LJ, Lin XX, Guo J, Xu Y, Zhang SX, Chen D, Zhao Q, Xiao J, Lian GH, Peng SF, Guo D, Yang H, Shu Y, Zhou HH, Zhang W, Chen Y. Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/β-catenin-Cyp2e1 Signaling. Int J Biol Sci 2021;17:3936-53. [PMID: 34671210 DOI: 10.7150/ijbs.63732] [Reference Citation Analysis]
7 Xin S, Zhan Q, Chen X, Xu J, Yu Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:186. [PMID: 32532204 DOI: 10.1186/s12876-020-01334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Li H, Xu QY, Xie Y, Luo JJ, Cao HX, Pan Q. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis. Ann Hepatol. 2021;24:100316. [PMID: 33515803 DOI: 10.1016/j.aohep.2021.100316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
10 Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Ye P, Xiao B, Mao W, Liu L, Yan Y, Chen G, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020;72:389-398. [PMID: 32359177 DOI: 10.1002/hep.31301] [Cited by in Crossref: 131] [Cited by in F6Publishing: 139] [Article Influence: 65.5] [Reference Citation Analysis]
11 Cai J, Lin C, Lai S, Liu Y, Liang M, Qin Y, Liang X, Tan A, Gao Y, Lu Z, Wu C, Huang S, Yang X, Zhang H, Kuang J, Mo Z. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis 2021;20:145. [PMID: 34706716 DOI: 10.1186/s12944-021-01568-9] [Reference Citation Analysis]
12 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Reply to "Does MAFLD really increase the severity of COVID-19?". Dig Liver Dis 2021;53:168. [PMID: 33187919 DOI: 10.1016/j.dld.2020.10.034] [Reference Citation Analysis]
13 Li T, Wang H, Dong S, Liang M, Ma J, Jiang X, Yu W. Protective effects of maslinic acid on high fat diet-induced liver injury in mice. Life Sci 2022;301:120634. [PMID: 35568228 DOI: 10.1016/j.lfs.2022.120634] [Reference Citation Analysis]
14 Yu Y, He C, Tan S, Huang M, Guo Y, Li M, Zhang Q, Amantini C. MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα. Analytical Cellular Pathology 2021;2021:1-13. [DOI: 10.1155/2021/4853355] [Reference Citation Analysis]
15 Hu X, Fan J, Ma Q, Han L, Cao Z, Xu C, Luan J, Jing G, Nan Y, Wu T, Zhang Y, Wang H, Zhang Y, Ju D. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J Nanobiotechnology 2022;20:237. [PMID: 35590366 DOI: 10.1186/s12951-022-01456-z] [Reference Citation Analysis]
16 Xiong Y, Peng Q, Cao C, Xu Z, Zhang B. Effect of Different Exercise Methods on Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression. Int J Environ Res Public Health 2021;18:3242. [PMID: 33801028 DOI: 10.3390/ijerph18063242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, Fang M, Yu Z, Rodrigues RM, Gao Y, Li M. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: a promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.001] [Reference Citation Analysis]
18 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
19 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig Liver Dis. 2021;53:153-157. [PMID: 33011088 DOI: 10.1016/j.dld.2020.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
20 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wu H, Lei Y, Mao J. Non-alcoholic fatty liver disease and intestinal immune status: a narrative review. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2032320] [Reference Citation Analysis]
22 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Park G, Jung S, Wellen KE, Jang C. The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease. Exp Mol Med 2021;53:809-22. [PMID: 34017059 DOI: 10.1038/s12276-021-00614-x] [Reference Citation Analysis]
24 Zhang JL, Du BB, Zhang DH, Li H, Kong LY, Fan GJ, Li YP, Li PC, Liang C, Wang Z, Yang LL, Hao ZY, Wu LM, Huang Z, Dong JZ, Zhang JY, Yao R, Wang SJ, Zhang YZ. OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. Hepatology 2021. [PMID: 34591986 DOI: 10.1002/hep.32179] [Reference Citation Analysis]
25 Zhang B, Ni M, Li X, Liu Q, Hu Y, Zhao Y. QSHY Granules Promote White Adipose Tissue Browning and Correct BCAAs Metabolic Disorder in NAFLD Mice. Diabetes Metab Syndr Obes 2021;14:4241-51. [PMID: 34703257 DOI: 10.2147/DMSO.S332659] [Reference Citation Analysis]
26 Hu C, Li X, Sui Y, Chen Y, Zhao Y, Yang Y, Zhou Q, Ni H, Sun L, Gan W, Li J, Liu Y. Dicer deletion in hepatocytes promotes macrophages M1 polarization through dysregulated miR-192-3p/IGF2 in non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Gene Ther 2022. [PMID: 35165388 DOI: 10.1038/s41417-022-00432-x] [Reference Citation Analysis]
27 Wei X, Zhang J, Tang M, Wang X, Fan N, Peng Y. Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα. Lipids Health Dis 2022;21. [DOI: 10.1186/s12944-022-01640-y] [Reference Citation Analysis]
28 Liu Y, Song J, Yang J, Zheng J, Yang L, Gao J, Tian S, Liu Z, Meng X, Wang JC, Dai Z, Tang YD. Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation. Hepatology 2021. [PMID: 33768585 DOI: 10.1002/hep.31832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
30 Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. Acta Pharmacol Sin 2021. [PMID: 33731774 DOI: 10.1038/s41401-021-00629-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Wang M, Wang M, Zhang R, Zhang L, Ding Y, Tang Z, Fan H, Wang H, Zhang W, Chen Y, Wang J. A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. PeerJ 2022;10:e13022. [DOI: 10.7717/peerj.13022] [Reference Citation Analysis]
32 Hong T, Chen Y, Li X, Lu Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxid Med Cell Longev 2021;2021:6889533. [PMID: 34745420 DOI: 10.1155/2021/6889533] [Reference Citation Analysis]
33 Wang Z, Yang Y, Zhang J, Hu J, Yan X, Zeng S, Huang X, Lin S. Ferulic acid ameliorates intrahepatic triglyceride accumulation in vitro but not in high fat diet-fed C57BL/6 mice. Food Chem Toxicol 2021;149:111978. [PMID: 33428987 DOI: 10.1016/j.fct.2021.111978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li W, Liu J, Cai J, Zhang XJ, Zhang P, She ZG, Chen S, Li H. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol 2021;163:118-32. [PMID: 34737121 DOI: 10.1016/j.yjmcc.2021.10.007] [Reference Citation Analysis]
35 Yu MM, Tang XL, Jin H, Yang S, Yun H, Wang QB, Zeng MS. Coronary CT Angiography in Asymptomatic Adults with Hepatic Steatosis. Radiology 2021;301:593-601. [PMID: 34546127 DOI: 10.1148/radiol.2021210355] [Reference Citation Analysis]
36 Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, Wu J. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. IJERPH 2022;19:2096. [DOI: 10.3390/ijerph19042096] [Reference Citation Analysis]
37 Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61. [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 Qiu P, Wang H, Zhang M, Zhang M, Peng R, Zhao Q, Liu J. FATP2-targeted therapies - A role beyond fatty liver disease. Pharmacol Res 2020;161:105228. [PMID: 33027714 DOI: 10.1016/j.phrs.2020.105228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhang Y, Fang XM. Hepatocardiac or Cardiohepatic Interaction: From Traditional Chinese Medicine to Western Medicine. Evid Based Complement Alternat Med 2021;2021:6655335. [PMID: 33777158 DOI: 10.1155/2021/6655335] [Reference Citation Analysis]
40 Zhou Y, Wu C, Wang X, Li P, Fan N, Zhang W, Liu Z, Zhang W, Tang B. Exploring the Changes of Peroxisomal Polarity in the Liver of Mice with Nonalcoholic Fatty Liver Disease. Anal Chem 2021;93:9609-20. [PMID: 34191493 DOI: 10.1021/acs.analchem.1c01776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
42 Dai X, Kuang Q, Sun Y, Xu M, Zhu L, Ge C, Tan J, Wang B. Fisetin represses oxidative stress and mitochondrial dysfunction in NAFLD through suppressing GRP78-mediated endoplasmic reticulum (ER) stress. Journal of Functional Foods 2022;90:104954. [DOI: 10.1016/j.jff.2022.104954] [Reference Citation Analysis]
43 Jarmakiewicz-czaja S, Sokal A, Pardak P, Filip R, Granito A. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/4344905] [Reference Citation Analysis]
44 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
45 Li M, Zhao Z, Qin G, Chen L, Lu J, Huo Y, Chen L, Zeng T, Xu M, Chen Y, Wang T, Wang S, Xu Y, Shi L, Tang X, Su Q, Yu X, Yan L, Wan Q, Chen G, Gao Z, Wang G, Shen F, Luo Z, Zhang Y, Liu C, Wang Y, Hu R, Ye Z, Wu S, Deng H, Yang T, Li Q, Qin Y, Mu Y, Zhao J, Ning G, Bi Y, Xu Y, Wang W. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. Metabolism 2021;124:154874. [PMID: 34517014 DOI: 10.1016/j.metabol.2021.154874] [Reference Citation Analysis]
46 Jiang W, Liu CH, Wu D, Wang YJ, Tang H. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep 2021;41:BSR20211769. [PMID: 34918746 DOI: 10.1042/BSR20211769] [Reference Citation Analysis]
47 Jin L, Sun Y, Li Y, Zhang H, Yu W, Li Y, Xin Y, Alsareii SA, Wang Q, Zhang D. A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides 2021;143:170597. [PMID: 34118361 DOI: 10.1016/j.peptides.2021.170597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 2021;18:38-44. [PMID: 33159158 DOI: 10.1038/s41423-020-00560-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
49 Li Y, Xu J, Lu Y, Bian H, Yang L, Wu H, Zhang X, Zhang B, Xiong M, Chang Y, Tang J, Yang F, Zhao L, Li J, Gao X, Xia M, Tan M, Li J. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab 2021;33:2004-2020.e9. [PMID: 34614409 DOI: 10.1016/j.cmet.2021.09.008] [Reference Citation Analysis]
50 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
51 Wan H, Wang Y, Zhang H, Zhang K, Chen Y, Chen C, Zhang W, Xia F, Wang N, Lu Y. Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. Ecotoxicology and Environmental Safety 2022;232:113257. [DOI: 10.1016/j.ecoenv.2022.113257] [Reference Citation Analysis]
52 Shanmugam H, Di Ciaula A, Di Palo DM, Molina-Molina E, Garruti G, Faienza MF, vanErpecum K, Portincasa P. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest 2021;51:e13597. [PMID: 34032283 DOI: 10.1111/eci.13597] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Tsai LW, Lu YH, Dubey R, Chiou JF. Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus. J Diabetes Res 2021;2021:7692447. [PMID: 34805412 DOI: 10.1155/2021/7692447] [Reference Citation Analysis]
54 Lan T, Yu Y, Zhang J, Li H, Weng Q, Jiang S, Tian S, Xu T, Hu S, Yang G, Zhang Y, Wang W, Wang L, Zhu Q, Rong X, Guo J. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway. Hepatology 2021;74:686-703. [PMID: 33576035 DOI: 10.1002/hep.31749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
55 Leng YR, Zhang MH, Luo JG, Zhang H. Pathogenesis of NASH and Promising Natural Products. Chin J Nat Med 2021;19:12-27. [PMID: 33516448 DOI: 10.1016/S1875-5364(21)60002-X] [Reference Citation Analysis]
56 Wu H, Xu X, Zheng A, Wang W, Mei L, Chen Y, Sun S, Jiang L, Wu Y, Zhou Y, Zheng M, Chen Q. TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. Hepatology 2021. [PMID: 33713358 DOI: 10.1002/hep.31801] [Reference Citation Analysis]
57 Wu L, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother 2021;136:111255. [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
58 Fan H, Diao H, Lu Y, Xie J, Cheng X. The relation between serum adipose differentiation-related protein and non-alcoholic fatty liver disease in type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2020;11:2042018820969025. [PMID: 33194172 DOI: 10.1177/2042018820969025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Shao M, Ye Z, Qin Y, Wu T. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review). Exp Ther Med 2020;20:26. [PMID: 32934691 DOI: 10.3892/etm.2020.9154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 He Z, Li X, Yang H, Wu P, Wang S, Cao D, Guo X, Xu Z, Gao J, Zhang W, Luo X. Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Nutr 2021;8:745609. [PMID: 34595203 DOI: 10.3389/fnut.2021.745609] [Reference Citation Analysis]
61 Zhou JC, Wang JL, Ren HZ, Shi XL. Autophagy plays a double-edged sword role in liver diseases. J Physiol Biochem 2021. [PMID: 34657993 DOI: 10.1007/s13105-021-00844-7] [Reference Citation Analysis]
62 Chen C, Xin X, Liu Q, Tian HJ, Peng JH, Zhao Y, Hu YY, Feng Q. Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1. Front Pharmacol 2021;12:653641. [PMID: 34017254 DOI: 10.3389/fphar.2021.653641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed JL, Yamaoka-tojo M, Matsunaga A, Ako J. The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. JCM 2022;11:1847. [DOI: 10.3390/jcm11071847] [Reference Citation Analysis]
64 Zhang J, Li Y, Xiao G, Li Y, Xie H, Chen Y. Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora. Liver Research 2021;5:217-23. [DOI: 10.1016/j.livres.2021.06.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Wang G, Wu S, Wu C, Zhang Q, Wu F, Yu B, Zhang S, Wu C, Wu G, Zhong Y. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med 2021. [PMID: 34761514 DOI: 10.1111/jcmm.17042] [Reference Citation Analysis]
66 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Reference Citation Analysis]
67 Hu C, Wang T, Zhuang X, Sun Q, Wang X, Lin H, Feng M, Zhang J, Cao Q, Jiang Y. Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry. J Transl Med 2021;19:152. [PMID: 33858428 DOI: 10.1186/s12967-021-02820-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
69 Li J, Qi J, Tang Y, Liu H, Zhou K, Dai Z, Yuan L, Sun C. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. J Nanobiotechnology 2021;19:363. [PMID: 34789275 DOI: 10.1186/s12951-021-01108-8] [Reference Citation Analysis]
70 Zhang L, Wang Y, Wu F, Wang X, Feng Y, Wang Y. MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila. Int J Biol Macromol 2022;196:23-34. [PMID: 34920070 DOI: 10.1016/j.ijbiomac.2021.12.036] [Reference Citation Analysis]
71 Rodrigues RM, He Y, Hwang S, Bertola A, Mackowiak B, Ait-Ahmed Y, Seo W, Ma J, Wang X, Park SH, Guan Y, Fu Y, Vanhaecke T, Feng D, Gao B. E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00169-7. [PMID: 34390865 DOI: 10.1016/j.jcmgh.2021.08.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Zhou YG, Tian N, Xie WN. Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. World J Hepatol 2022; 14(4): 791-801 [DOI: 10.4254/wjh.v14.i4.791] [Reference Citation Analysis]
73 Li HY, Gan RY, Shang A, Mao QQ, Sun QC, Wu DT, Geng F, He XQ, Li HB. Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application. Oxid Med Cell Longev 2021;2021:6621644. [PMID: 33728021 DOI: 10.1155/2021/6621644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, Huang M. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. Bioengineered 2022;13:2927-42. [PMID: 35038955 DOI: 10.1080/21655979.2021.2017698] [Reference Citation Analysis]
75 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
76 Zhu K, Guo Y, Zhao C, Kang S, Li J, Wang J, Tang Z, Lin B, Li W. Etiology Exploration of Non-alcoholic Fatty Liver Disease From Traditional Chinese Medicine Constitution Perspective: A Cross-Sectional Study. Front Public Health 2021;9:635818. [PMID: 34055713 DOI: 10.3389/fpubh.2021.635818] [Reference Citation Analysis]
77 Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134:8-19. [PMID: 33323806 DOI: 10.1097/cm9.0000000000001263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Wang W, Hu M, Liu H, Zhang X, Li H, Zhou F, Liu YM, Lei F, Qin JJ, Zhao YC, Chen Z, Liu W, Song X, Huang X, Zhu L, Ji YX, Zhang P, Zhang XJ, She ZG, Yang J, Yang H, Cai J, Li H. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab 2021;33:1943-1956.e2. [PMID: 34478633 DOI: 10.1016/j.cmet.2021.08.005] [Reference Citation Analysis]
80 Xue LJ, Han JQ, Zhou YC, Peng HY, Yin TF, Li KM, Yao SK. Untargeted metabolomics characteristics of nonobese nonalcoholic fatty liver disease induced by high-temperature-processed feed in Sprague-Dawley rats. World J Gastroenterol 2020; 26(46): 7299-7311 [PMID: 33362385 DOI: 10.3748/wjg.v26.i46.7299] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Shan D, Wang J, Di Q, Jiang Q, Xu Q. Steatosis induced by nonylphenol in HepG2 cells and the intervention effect of curcumin. Food Funct 2021. [PMID: 34904613 DOI: 10.1039/d1fo02481g] [Reference Citation Analysis]
82 Molina-Molina E, Shanmugam H, Di Ciaula A, Grattagliano I, Di Palo DM, Palmieri VO, Portincasa P. (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle. JHEP Rep 2021;3:100203. [PMID: 33490935 DOI: 10.1016/j.jhepr.2020.100203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Huang H, Wang Q, Shi X, Chen Y, Shen C, Zhang J, Xu C. Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Mediators Inflamm 2021;2021:6642246. [PMID: 34916874 DOI: 10.1155/2021/6642246] [Reference Citation Analysis]
84 Wu F, Xu L, Tu Y, Cheung OK, Szeto LL, Mok MT, Yang W, Kang W, Cao Q, Lai PB, Chan SL, Tan P, Sung JJ, Yip KY, Cheng AS, To KF. Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Lett 2021;525:115-30. [PMID: 34736960 DOI: 10.1016/j.canlet.2021.10.039] [Reference Citation Analysis]
85 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]